Bionomics Wins Awards at Major BioPharma Asia Convention

ADELAIDE, South Australia, March 13, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) has been named as the Innovative Asian Biotech of the Year at this week's BioPharma Asia Industry Awards during the BioPharma Asia Convention, at the Suntec Convention and Exhibition Centre in Singapore.

BioPharma Asia Convention is Asia's largest biopharmaceutical event drawing almost 3,000 attendees from across the world with interests in biotech and pharmaceutical company partnering, industry trends and investment opportunities.

The citation underpinning the Innovative Asian Biotech of the Year award made reference to Bionomics' ability to adopt innovative technologies to develop novel drugs. It is also acknowledged the company's approach to drug development including the implementation of new processes, technologies or applications that achieve quantifiable and sustainable results.

Further, CEO & Managing Director Dr Deborah Rathjen was awarded the Life Science Woman Executive of the Year award for her contribution to both the biopharma industry and society. Conference leaders cited achievement of excellent results while demonstrating high levels of professionalism.

The awards were collected on behalf of Bionomics and Dr Rathjen by the company's Vice President of Research and Development Dr Gabriel Kremmidiotis. The awards are part of the annual BioPharma Asia Industry Convention at which Dr Kremmidiotis also delivered a company presentation on Bionomics.

"Bionomics has continued on an upward trajectory over the past 12 months with milestones right across our pipeline," said Dr Rathjen.

"These awards recognise the dedication and hard work of our team and we expect to continue substantial progress moving forward."

About Bionomics Limited

Bionomics (ASX:BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX® , a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co and Ironwood Pharmaceuticals.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co and Ironwood Pharmaceuticals, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Ironwood's decisions to continue or not continue development of IW-2143, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

CONTACT: FOR FURTHER INFORMATION PLEASE CONTACT: Bionomics Limited Dr Deborah Rathjen CEO & Managing Director +618 8354 6101 / 0418 160 425 drathjen@bionomics.com.au Monsoon Communications Rudi Michelson +613 9620 3333 rudim@monsoon.com.au The Trout Group Lauren Glaser +1 646 378 2972 lglaser@troutgroup.comSource:Bionomics Limited